Drug prices jumped about 13 percent in the United States last year, spurring a public outcry and moving the issue onto the campaign platform of Hillary Clinton and other U.S. Presidential candidates for the November 2016 election. US health insurer, Cigna, and Novartis, the Swiss drug maker, have agreed on a performance-based price for its new heart drug, Entresto. Payments will be based on the reduction in the proportion of Cigna customers who are admitted to hospital for heart failure. The deal is expected to save $400m (£264m) over five years, but it has been criticised by some cardiologists as being too generous.
US health insurer, Cigna, and Novartis, the Swiss drug maker, have agreed on a performance-based price for its new heart drug, Entresto. Payments will be based on the reduction in the proportion of Cigna customers who are admitted to hospital for heart failure. The deal is expected to save $400m (£264m) over five years, but it has been criticised by some cardiologists as being too generous.